Practical management of behavioral problems in mucopolysaccharidoses disorders

Molecular Genetics and Metabolism

Volumn 122, Issue , 2017, Pages 35-40

  Escolar, Maria L ^a   Jones, Simon A ^b   Shapiro, Elsa G ^c,d   Horovitz, Dafne D G ^e   Lampe, Christina ^f   Amartino, Hernán ^g  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Shapiro Neuropsychology Consultants   (United States)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f DR HORST SCHMIDT KLINIKEN   (Germany)

^g UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Behavior; Child behavior disorders; Lysosomal storage diseases; Mental disorders; Mucopolysaccharidoses

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; CENTRAL DEPRESSANT AGENT; GLYCOSAMINOGLYCAN;

ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; ENVIRONMENTAL CHANGE; FAMILY; FRUSTRATION; HUMAN; HYPERACTIVITY; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL; PROBLEM BEHAVIOR; REVIEW; SLEEP DISORDER; BRAIN; CHILD; CHILD BEHAVIOR; COMPLICATION; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; METABOLISM; ORGANIZATION; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

BEHAVIOR THERAPY; BRAIN; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; CONGRESSES AS TOPIC; DYSSOMNIAS; GLYCOSAMINOGLYCANS; HUMANS; MUCOPOLYSACCHARIDOSES; TREATMENT OUTCOME;

EID: 85034592051     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2017.09.010     Document Type: Review

References (56)

1. Neufeld, E.F., Muenzer, J., The mucopolysaccharidoses. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic and Molecular Bases of Inherited Disease, 2001, McGraw-Hill Medical Publishing Division, New York, 3421–3452.
2. Muenzer, J., Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50:Suppl. 5 (2011), v4–v12.
3. Zafeiriou, D.I., Batzios, S.P., Brain and spinal MR imaging findings in mucopolysaccharidoses: a review. AJNR Am. J. Neuroradiol. 34 (2013), 5–13.
4. Muenzer, J., The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J. Pediatr. 144:5 Suppl (2004), S27–S34.
5. Davison, J.E., Kearney, S., Horton, J., Foster, K., Peet, A.C., Hendriksz, C.J., Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J. Inherit. Metab. Dis. 36 (2013), 323–328.
6. Bax, M.C.O., Colville, G.A., Behaviour in mucopolysaccharide disorders. Arch. Dis. Child. 73 (1995), 77–81.
7. Węgrzyn, G., Jakóbkiewicz-Banecka, J., Narajczyk, M., Wiśniewski, A., Piotrowska, E., Gabig-Cimińska, M., Kloska, A., Słomińska-Wojewódzka, M., Korzon-Burakowska, A., Węgrzyn, A., Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?. Med. Hypotheses 75 (2010), 605–609.
8. Gilkes, J.A., Heldermon, C.D., Mucopolysaccharidosis III (Sanfilippo syndrome) - disease presentation and experimental therapies. Pediatr. Endocrinol. Rev. 12:Suppl. 1 (2014), 133–140.
9. Holt, J.B., Poe, M.D., Escolar, M.L., Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127 (2011), e1258–1265.
10. Shapiro, E.G., Nestrasil, I., Rudser, K., Delaney, K., Kovac, V., Ahmed, A., Yund, B., Orchard, P.J., Eisengart, J., Niklason, G.R., Raiman, J., Mamak, E., Cowan, M.J., Bailey-Olson, M., Harmatz, P., Shankar, S.P., Cagle, S., Ali, N., Steiner, R.D., Wozniak, J., Lim, K.O., Whitley, C.B., Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol. Genet. Metab. 116 (2015), 61–68.
11. Shapiro, E.G., Lockman, L.A., Balthazor, M., Krivit, W., Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 18 (1995), 413–429.
12. Wallace, S.P., Prutting, C.A., Gerber, S.E., Degeneration of speech, language, and hearing in a patient with mucopolysaccharidosis VII. Int. J. Pediatr. Otorhinolaryngol. 19 (1990), 97–107.
13. Bruyère, J., Roy, E., Ausseil, J., Lemonnier, T., Teyre, G., Bohl, D., Etienne-Manneville, S., Lortat-Jacob, H., Heard, J.M., Vitry, S., Heparan sulfate saccharides modify focal adhesions: implication in mucopolysaccharidosis neuropathophysiology. J. Mol. Biol. 427 (2015), 775–791.
14. Wilkinson, F.L., Holley, R.J., Langford-Smith, K.J., Badrinath, S., Liao, A., Langford-Smith, A., Cooper, J.D., Jones, S.A., Wraith, J.E., Wynn, R.F., Merry, C.L.R., Bigger, B.W., Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB. PLoS One, 7, 2012, e35787.
15. Cross, E.M., Hare, D.J., Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J. Inherit. Metab. Dis. 36 (2013), 189–200.
16. Malcolm, C., Hain, R., Gibson, F., Adams, S., Anderson, G., Forbat, L., Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families. Acta Paediatr. 101 (2012), 985–992.
17. Roberts, J., Stewart, C., Kearney, S., Management of the behavioural manifestations of Hunter syndrome. Br. J. Nurs., 25, 2016 (22, 24, 26–30).
18. Shapiro, E.G., Jones, S.A., Escolar, M.L., Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - neurological signs and symptoms. Mol. Genet. Metab. 122 (2017), 1–7.
19. Rapoport, D., Mitchell, J.J., Pathophysiology, evaluation and management of sleep disorders in the mucopolysaccharidoses. Mol. Genet. Metab. 122 (2017), 49–54.
20. Muenzer, J., Beck, M., Eng, C.M., Escolar, M.L., Giugliani, R., Guffon, N.H., Harmatz, P., Kamin, W., Kampmann, C., Koseoglu, S.T., Link, B., Martin, R.A., Molter, D.W., Muñoz Rojas, M.V., Ogilvie, J.W., Parini, R., Ramaswami, U., Scarpa, M., Schwartz, I.V., Wood, R.E., Wraith, E., Multidisciplinary management of Hunter syndrome. Pediatrics 124 (2009), e1228–e1239.
21. Young, I.D., Harper, P.S., Psychosocial problems in Hunter's syndrome. Child Care Health Dev. 7 (1981), 201–209.
22. Valstar, M.J., Neijs, S., Bruggenwirth, H.T., Olmer, R., Ruijter, G.J.G., Wevers, R.A., van Diggelen, O.P., Poorthuis, B.J., Halley, D.J., Wijburg, F.A., Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann. Neurol. 68 (2010), 876–887.
23. Moog, U., van Mierlo, I., van Schrojenstein Lantman-de Valk, H.M.J., Spaapen, L., Maaskant, M.A., Curfs, L.M.G., Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?. Am. J. Med. Genet. C Semin. Med. Genet. 145C (2007), 293–301.
24. Young, I.D., Harper, P.S., The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 25 (1983), 481–489.
25. Potegal, M., Yund, B., Rudser, K., Ahmed, A., Delaney, K., Nestrasil, I., Whitley, C.B., Shapiro, E.G., Mucopolysaccharidosis type IIIA presents as a variant of Klüver-Bucy syndrome. J. Clin. Exp. Neuropsychol. 35 (2013), 608–616.
26. Shapiro, E., King, K., Ahmed, A., Rudser, K., Rumsey, R., Yund, B., Delaney, K., Nestrasil, I., Whitley, C., Potegal, M., The neurobehavioral phenotype in mucopolysaccharidosis type IIIB: an exploratory study. Mol. Genet. Metab. Rep. 6 (2016), 41–47.
27. Fraser, J., Gason, A.A., Wraith, J.E., Delatycki, M.B., Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study. Arch. Dis. Child. 90 (2005), 1239–1242.
28. Nidiffer, F.D., Kelly, T.E., Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: an epidemiological study. J. Ment. Defic. Res. 27:Pt 3 (1983), 185–203.
29. Colville, G.A., Watters, J.P., Yule, W., Bax, M., Sleep problems in children with Sanfilippo syndrome. Dev. Med. Child Neurol. 38 (1996), 538–544.
30. Holt, J., Poe, M.D., Escolar, M.L., Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II. J. Pediatr. 159 (2011), 320–326.
31. Mahon, L.V., Lomax, M., Grant, S., Cross, E., Hare, D.J., Wraith, J.E., Jones, S., Bigger, B., Langford-Smith, K., Canal, M., Assessment of sleep in children with mucopolysaccharidosis type III. PLoS One, 9, 2014, e84128.
32. Chang, W.P., Liu, M.E., Chang, W.C., Yang, A.C., Ku, Y.C., Pai, J.T., Huang, H.L., Tsai, S.J., Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan. PLoS One, 8, 2013, e78655.
33. Foley, D., Monjan, A., Masaki, K., Ross, W., Havlik, R., White, L., Launer, L., Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J. Am. Geriatr. Soc. 49 (2001), 1628–1632.
34. Buhrman, D., Thakkar, K., Poe, M., Escolar, M.L., Natural history of Sanfilippo syndrome type A. J. Inherit. Metab. Dis. 37 (2014), 431–437.
35. Shapiro, E.G., Nestrasil, I., Delaney, K.A., Rudser, K., Kovac, V., Nair, N., Richard, C.W., III, P. Haslett, Whitley, C.B., A prospective natural history study of mucopolysaccharidosis type IIIA. J. Pediatr. 170 (2016), 278–287.
36. Grant, S., Cross, E., Wraith, J.E., Jones, S., Mahon, L., Lomax, M., Bigger, B., Hare, D., Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID). J. Inherit. Metab. Dis. 36 (2013), 281–291.
37. Cleary, M.A., Wraith, J.E., Management of mucopolysaccharidosis type III. Arch. Dis. Child. 69 (1993), 403–406.
38. Robertson, S.P., Klug, G.L., Rogers, J.G., Cerebrospinal fluid shunts in the management of behavioural problems in Sanfilippo syndrome (MPS III). Eur. J. Pediatr. 157 (1998), 653–655.
39. Grioni, D., Contri, M., Furlan, F., Rigoldi, M., Rovelli, A., Parini, R., Epilepsy in mucopolysaccharidosis: clinical features and outcome. Parini, R., Andria, G., (eds.) Lysosomal Storage Diseases: Early Diagnosis and New Treatments, 2010, John Libbey Eurotext, Montrouge, 73–80.
40. Kaplan, P.W., Prognosis in nonconvulsive status epilepticus. Epileptic Disord. 2 (2000), 185–193.
41. Krishnamurthy, K.B., Epilepsy. Ann. Intern. Med. 164 (2016), ITC17–32.
42. Fisher, R.S., van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., Engel, J. Jr., Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46 (2005), 470–472.
43. Bonanni, P., Volzone, A., Randazzo, G., Antoniazzi, L., Rampazzo, A., Scarpa, M., Nobili, L., Nocturnal frontal lobe epilepsy in mucopolysaccharidosis. Brain Dev. 36 (2014), 826–829.
44. Leighton, S.E.J., Papsin, B., Vellodi, A., Dinwiddie, R., Lane, R., Disordered breathing during sleep in patients with mucopolysaccharidoses. Int. J. Pediatr. Otorhinolaryngol. 58 (2001), 127–138.
45. Ylvisaker, M., Turkstra, L., Coehlo, C., Yorkston, K., Kennedy, M., Sohlberg, M.M., Avery, J., Behavioural interventions for children and adults with behaviour disorders after TBI: a systematic review of the evidence. Brain Inj. 21 (2007), 769–805.
46. Wiggs, L., Stores, G., Severe sleep disturbance and daytime challenging behaviour in children with severe learning disabilities. J. Intellect. Disabil. Res. 40:Pt 6 (1996), 518–528.
47. Rumsey, R.K., Rudser, K., Delaney, K., Potegal, M., Whitley, C.B., Shapiro, E., Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. J. Pediatr. 164 (2014), 1147–1151 (e1141).
48. Kalkan Ucar, S., Ozbaran, B., Demiral, N., Yuncu, Z., Erermis, S., Coker, M., Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status. Brain Dev. 32 (2010), 156–161.
49. Tchan, M.C., Sillence, D., Extrapyramidal symptoms and medication use in mucopolysaccharidosis type III. J. Intellect. Develop. Disabil. 34 (2009), 275–279.
50. Hier, D.B., Ahluwalie, S., Melyn, M., Hoganson, G.E. Jr., Estrogens control aggressive behavior in some patients with Sanfilippo syndrome. Neurol. Res. 21 (1999), 611–612.
51. Kushner, S.A., Guze, B.H., Treatment of psychomotor agitation and self-injurious behavior with estrogen and progesterone in a patient with Sanfilippo syndrome. Gen. Hosp. Psychiatry 27 (2005), 298–300.
52. McEwen, B., Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57 (2002), 357–384.
53. Guerrero, J.M., Pozo, D., Diaz-Rodriguez, J.L., Martinez-Cruz, F., Vela-Campos, F., Impairment of the melatonin rhythm in children with Sanfilippo syndrome. J. Pineal Res. 40 (2006), 192–193.
54. Fraser, J., Wraith, J.E., Delatycki, M.B., Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin. Genet. 62 (2002), 418–421.
55. The Triple P-Positive Parenting Program. http://www.triplep-parenting.net/glo-en/triple-p/ (last accessed January 2017).
56. Sanders, M.R., Triple p-positive parenting program: towards an empirically validated multilevel parenting and family support strategy for the prevention of behavior and emotional problems in children. Clin. Child. Fam. Psychol. Rev. 2 (1999), 71–90.